Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Sells $80,244.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the sale, the chief executive officer now owns 5,501,715 shares of the company’s stock, valued at $66,020,580. This trade represents a 0.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $11.01 on Friday. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -8.60 and a beta of 1.41. The business’s 50 day simple moving average is $9.92 and its 200-day simple moving average is $8.08. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Institutional Trading of Alphatec

Institutional investors have recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Alphatec during the 4th quarter worth $29,000. Nisa Investment Advisors LLC raised its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 4,234 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Alphatec in the third quarter valued at about $69,000. Net Worth Advisory Group acquired a new stake in shares of Alphatec in the third quarter valued at approximately $76,000. Finally, Van ECK Associates Corp increased its stake in shares of Alphatec by 57.0% during the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after purchasing an additional 6,998 shares in the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ATEC shares. Barclays raised their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday. Needham & Company LLC raised their price target on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.